A birth control coverage opt-out for employers was finalized by the Trump administration on Wednesday.
The expanded approval was supposed by safety and efficacy data from the Phase 3 ACCESS IUS trial (N=1751) in women receiving Liletta. In the trial, Liletta demonstrated >99% efficacy in preventing pregnancy for up to 5 years in a broad patient population.
Continuous or extended combined oral contraceptive regimens not linked to higher venous thromboembolism riskOctober 11, 2018
In this retrospective cohort study, continuous (84/7) or extended (365/0) cycle regimens of combined oral contraceptives were not linked with meaningfully higher rates of venous thromboembolism when compared with traditional cyclic (21/7) regimens.
Combined hormonal contraception use tied to lower risk; risk down with increasing duration of use.
Increases in use of 1 or more contraceptive methods, dual-method use, long-acting reversibles.
Current oral contraceptive products contain lower doses of estrogen than those used in the past, prompting reconsideration of risks and benefits.
An evaluation assessed the nonhealthcare-related influences that have led to misconceptions about long-acting reversible contraceptives.
Increase in use depends on the amount of reduction in out-of-pocket costs
Because of the high number of unintended pregnancies and the effectiveness of LARCs, they should be a first-line contraceptive option for most women.
Breast cancer diagnosis is higher among women who currently use or recently used contemporary hormonal contraceptives than among women who have never used hormonal contraceptives.
The CDC revised its US Medical Eligibility Criteria for Contraceptive Use categorization for DMPA injection in women at high risk for HIV infection from US MEC category 1 to US MEC category 2.
The practice bulletin provides information for appropriate patient selection and evidence-based recommendations for intrauterine devices and contraceptive implants.
Use of oral contraceptives did not increase the risk for cancer in women and decreased the risk for colorectal, endometrial, ovarian, and lymphatic and hematopoietic cancers.
LARC is safe and effective in nulliparous adolescents and should be considered as a viable alternative to oral contraception.
Women with Crohn disease who use oral contraceptives for more than 1 year have an increased risk of surgery.
Levonorgestrel, low-dose estrogen associated with lower risk for adverse vascular events among oral contraceptivesJune 04, 2016
Compared with other estrogen doses and progestogen types, low-dose estrogen with levonorgestrel had a decreased risk of adverse events.
A form of male birth control called Vasalgel, which works by injecting a polymer gel into the vas deferens, is being developed in the United States.
The agency will require Bayer to conduct clinical studies examining the device's benefits and harms.
More readers weigh in on the ethical issues surrounding the use of intrauterine devices.
Starting January 1, the state of Oregon no longer requires a prescription for birth control for women 18 years of age and older.
For women who are pro-life advocates, copper IUD devices that prevent fertilization may be an acceptable alternative.
Expanding Medicaid coverage will allow more low-income women the choice to get an IUD implant immediately after birth.
More Medicaid plans are offering reimbursement for women who choose to get long-term contraception implants immediately after giving birth.
Disseminating accurate information can help women make informed decisions and potentially increase the overall use of intrauterine devices.
Although they have sex with the same frequency as other girls, obese teens are less likely to use contraception.
Women taking contraceptive pills that contain newer types of progestogen have higher clot risks.
Nearly 87 million women face an unplanned pregnancy due to the underuse of contraception each year,.
Barriers include knowledge deficits, cost and insurance coverage, unnecessary medical testing.
The pill is still the most popular birth control method of choice.
Nearly 40% of women do not have access to free long-acting contraceptives.